NasdaqGS:HALOBiotechs
Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model?
In July 2026, Halozyme Therapeutics announced a global collaboration and licence agreement with Incyte to apply its ENHANZE drug delivery technology to develop additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms, with Halozyme eligible for upfront, milestone and royalty payments on future commercial products.
This partnership underlines how Halozyme can integrate its ENHANZE platform into precision oncology...